Ozempic face: what it is, why it happens and what helps

“Ozempic face” is the popular name for a hollow, deflated look in the face after large, fast weight loss on a GLP-1 drug such as Ozempic, Wegovy or Zepbound. It comes from losing facial fat along with body fat, not from a direct effect of the drug: a 2026 review of 46 reports found the same changes after other kinds of substantial weight loss, including bariatric surgery (Yoo, Aesthetic Surgery Journal 2026). Dermatologists commonly treat it with dermal fillers, which are FDA-approved medical devices, though the studies in GLP-1 users are small and uncontrolled.

What is Ozempic face?

The phrase covers three changes people notice as the scale drops: hollowing in the cheeks and midface, looser skin, and deeper folds, such as the lines that run from the nose to the corners of the mouth. A 2026 dermatology review describes the same picture: volume loss, skin laxity and loss of structural support (Fathizadeh et al., Clinics in Dermatology 2026).

It is a nickname, not a diagnosis. The term appears on no GLP-1 label, and it is not specific to Ozempic, which is semaglutide approved for type 2 diabetes rather than weight loss (Ozempic label, rev. 05/2026). The same changes are reported with Wegovy, the semaglutide brand approved for weight, and with tirzepatide, sold as Zepbound for weight and Mounjaro for diabetes.

Why it happens: fat loss, not a drug reaction

GLP-1 drugs lower weight mainly by cutting appetite and how much people eat. The Wegovy and Zepbound labels both say the drug “lowers body weight with greater fat mass loss than lean mass loss.” The face holds several layers of fat, and they shrink along with fat everywhere else.

The amount of weight lost in the label trials is large:

Scroll sideways to see the full table

Sources: Wegovy label Table 8, Study 2 (rev. 06/2026); Zepbound label Table 2, Study 1 (rev. 08/2026). Both trials enrolled adults with obesity, or overweight with a weight-related condition.

Imaging puts numbers on the face itself. In the 2026 review, repeat scans of 20 patients showed a median 9% loss of midface volume, with more loss in the outer (superficial) fat layers, 11%, than in the deep ones, 7%. A regression across the data estimated about 7% of midface volume lost for every 10 kg (22 lb) of body weight lost.

Age and the size of the loss seem to matter. Studies after bariatric surgery describe facial deflation and an older look, most of all in older patients and after larger losses. The review’s author concludes that weight-loss deflation sits on top of each person’s own anatomy and aging. Whether losing weight faster makes it worse, apart from losing more of it, is still uncertain. The Clinics in Dermatology review adds changes in the fat layer just under the skin, bone remodeling and muscle loss to the picture.

How common is Ozempic face?

Nobody knows the exact rate. The label trials did not measure facial appearance, and no study has counted how often it happens across all GLP-1 users. What exists is survey data:

• A survey of 1,226 people found more reports of facial volume loss and laxity among those who lost a larger share of their body weight (reported in Yoo 2026).
• A survey of 406 US clinicians who treat cosmetic patients (100 dermatologists, 100 plastic surgeons, 105 other physicians and 101 nurses or physician assistants) ranked midface volume loss and face and neck skin laxity as the changes GLP-1s affect most. They reported a mean 137% rise in their patients taking GLP-1s from 2023 to 2024. Two of the authors worked for a filler maker (Fabi et al., Dermatologic Surgery 2026).

Ozempic butt and other body changes

“Ozempic butt” is the same process below the waist: as fat shrinks, the buttocks can look flatter and the skin looser. In the clinician survey above, loose or sagging body skin ranked alongside the facial changes, and patients also raised stubborn pockets of fat.

Options for the body are narrower than for the face. The FDA recommends against using dermal fillers or any injectable filler to increase the size of the buttocks. It has not approved injectable silicone for any cosmetic procedure, and warns that silicone injections can cause long-term pain, infections, scarring, permanent disfigurement, blocked blood vessels, stroke and death (FDA).

Dermal fillers for Ozempic face: FDA status

Dermal fillers are medical device implants. The FDA approves specific products for specific uses in adults 22 and older (FDA), including:

• Moderate to severe facial wrinkles and folds, such as the nasolabial folds.
• Adding volume to the lips, cheeks, chin and back of the hand.
• Restoring facial fat loss (lipoatrophy) in people with HIV.

None of the approved uses names weight-loss changes, so a clinician treating “Ozempic face” relies on approvals for areas such as the cheeks and folds. No filler is approved for over-the-counter use, and needle-free injection devices are not approved for fillers.

Scroll sideways to see the full table

Source: FDA-approved dermal fillers and the FDA dermal filler page.

Dermatology reviews call calcium hydroxylapatite and PLLA collagen stimulators, or biostimulators, because they are meant to prompt the skin to build collagen rather than only fill space (Bommareddy et al., J Clin Aesthet Dermatol 2026). In the clinician survey, hyaluronic acid was rated the best treatment for facial concerns for an average of 47% of patients.

What the evidence shows

The evidence in GLP-1 users is thin. A 2026 systematic review found 4 uncontrolled studies with 98 treated people. All reported improvement within the treated group, but none had a comparison group, so the authors could not say which treatment works or works best (Maglitto et al., Aesthetic Plastic Surgery 2026).

One example: a 2026 case series followed 15 women aged 30 to 50 in Latin America who had lost an average 17.9% of their weight on GLP-1s and then received PLLA plus hyaluronic acid. Researchers scored photos at about 90 days on a facial laxity scale, where the average fell from 4.5 to 2.6, and recorded bruising and swelling that cleared within 72 hours. Several authors worked for or were paid by the filler’s maker (Avelar et al., 2026).

Filler risks

The FDA lists bruising, redness, swelling, pain, tenderness, itching and rash as common risks. The most serious is accidental injection into a blood vessel, which can cause tissue death, vision problems including blindness, and stroke. Its advice for patients:

• Choose a licensed clinician with experience in dermatology or plastic surgery, and treat filler as a medical procedure.
• Never inject yourself or buy filler online. The FDA has found unapproved filler products sold in the US.
• Get care right away for unusual pain, vision changes, white, gray or blue skin near the injection, or any sign of stroke.

How to avoid Ozempic face

No trial has tested a way to prevent it, so treat any product or plan that promises to with caution. A few steps fit what the evidence does show:

• Protect muscle and nutrition. A 2025 joint advisory from four obesity and nutrition societies lists preserving muscle and bone through resistance training and an appropriate diet, and preventing nutrient deficiencies, as priorities during GLP-1 treatment (Mozaffarian et al., Am J Clin Nutr 2025).
• Set a weight goal with your clinician. Facial volume loss tracked the amount of weight lost, about 7% of midface volume per 10 kg in one analysis.
• Follow your prescribed dose steps. The labels raise doses gradually to limit stomach side effects. There is no evidence that a slower schedule protects your face, so don’t change your dose on your own.
• Ask about timing. If you plan to see a dermatologist, ask how continuing weight loss affects when treatment makes sense.

Weighing it up

Facial change is a cosmetic cost of losing a lot of weight by any method. The decision about a GLP-1 rests more on the label’s safety warnings, led by a boxed warning for thyroid C-cell tumors, which our GLP-1 side effects guide covers. Talk to your prescriber before stopping because of how your face looks: the nutrition advisory notes that low long-term adherence is often followed by weight regain. Some people also notice hair shedding during GLP-1 weight loss, which has a similar cause.

When you are ready to compare programs, our list of the best GLP-1 programs orders the ones we list by our published rating method, and the weight loss hub has the rest of our guides.

The bottom line

“Ozempic face” is facial fat loss that comes with large weight loss, not a reaction specific to Ozempic or any one GLP-1. Imaging suggests about 7% of midface volume goes for every 10 kg lost, and older people and those who lose the most seem to notice it most. FDA-approved fillers such as hyaluronic acid, calcium hydroxylapatite and PLLA can restore volume in approved areas, but studies in GLP-1 users are small and uncontrolled. Choose an experienced, licensed injector, skip fillers and silicone for the buttocks, and keep your prescriber in the loop.